Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 2...
Two leaders in lipid nanoparticle (LNP) development have partnered to make PEG-free shielding lipids available to researchers advancing LNPs for non-vira...
Gilead Sciences celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the co...
-Biocytogen Pharmaceuticals), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative techn...
MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) announced that the two companies have signed an exclus...
Highly Complementary Technologies Strengthen Thermo Fisher’s Portfolio in Bioprocessing and Adjacent Markets Thermo Fisher Scientific Inc. , the w...
Expanded Strategic Partnership Enables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers Thermo Fisher Scien...
Secures third contract this year, reinforcing global competitiveness and expanding strategic partnerships LOTTE BIOLOGICS (CEO James Park) announce...
AmeriWater, a leading provider of advanced water purification systems for healthcare, is pleased to announce it has signed an agreement with Vizient®...
Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingw...
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a pa...
Scenic Biotech, a pioneer in modifier therapies for severe diseases, announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDA...
The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe...
© 2025 Biopharma Boardroom. All Rights Reserved.
